Review on chemogenomics approach: interpreting antagonist activity of secreted frizzled-related protein 1 in glaucoma disease with in-silico docking.
Computer-aided drug discovery is a growing frontier in science. It covers different sub areas like chemoinformatics and chemogenomics. Chemogenomics is one of the emerging inter-disciplinary approaches in drug discovery, which combines conventional ligand based approach with biological information of drug targets. The main goal of this review is to check effective application of chemogenomics in understanding interactions between all possible ligands and their potential drug targets at molecular level. Recent studies revealed that increased expression of sFRP1an inhibitor of Wnt signalling pathway, seems to be responsible for Elevated Intracellular Pressure (IOP) in glaucoma patients. Glaucoma is a worldwide spread disease. Here, secreted frizzled-related protein-1 (sFRP1) has been used as a target protein. An important role of sFRP1, an antagonist of Wnt signalling pathway, has been found in regulating IOP. Wnt3a ligand protein and a natural compound from marine source Mycaperoxide H - have been used as ligands. In-silico docking of these ligands with sFRP family implies answers to many intricate queries in drug development field. Using above mentioned ligand-protein model in this study, application of chemogenomics has tried to explore the interaction of active site of proteins with the novel ligands. Henceforth, the present review will focus on predictive in-silico chemogenomic approaches with computer aided drug design could be used in drug design domain in identifying new targets in various diseases, in time and cost effective manner.